BUSINESS
Pipeline
Tisolagiline (KDS2010)
  • Feasibility
  • Preclinical
  • Phase I
  • Phase II
  • Phase III
Obesity1), 2)

  • Phase II IND approved
Alzheimer's disease1), 2)

  • Phase II IND approved
Post stroke1)
Spinal cord injury1)
Parkinson's disease1)
Multiple sclerosis1)
Post Traumatic
Stress Disorder1), 2)
Depression1), 2)
1) Conducted in Korea, 2) Conducted in US